There is a growing evidence that molecular markers such as IDH1/2 mutations, MGMT promoter methylation, TERT promoter mutational status or 1p/19q co-deletion are important for diagnosis and prognosis of glioma patients1. This evidence concerns the gene MGMT and glioma.